EOLS vs ACLX vs ABBV vs LEGN

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, AbbVie Inc.

is actually cheaper at 14. 3x.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -30. 1% for Evolus, Inc. (EOLS). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus EOLS's -44. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus Evolus, Inc. 's 1. 27β — meaning EOLS is approximately -476% more volatile than ACLX relative to the S&P 500. On balance sheet safety, Arcellx, Inc. (ACLX) carries a lower debt/equity ratio of 24% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: Evolus, Inc. grew EPS 1. 2% year-over-year, compared to -103. 5% for Arcellx, Inc.. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 3x forward P/E versus 118. 1x for Legend Biotech Corporation — 103. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EOLS: 134. 7% to $15. 00.

In this comparison, ABBV (3.

2% yield) pays a dividend. EOLS, ACLX, LEGN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). Both have compounded well over 10 years (ACLX: +584. 9%, EOLS: -44. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EOLS is a small-cap quality compounder stock; ACLX is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; LEGN is a small-cap high-growth stock. ABBV pays a dividend while EOLS, ACLX, LEGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.